Babson KA, Sottil J, Morabito D. (2017). Cannabis, Cannabinoids, and Sleep: A Review of the Literature. Current Psychiatry Rep 19(4):23. Retrieved June 15, 2020 from https://pubmed.ncbi.nlm.nih.gov/28349316/.

Bachuber M, Saloner B, Chinazo O, et al. (2014). Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999–2010. JAMA Intern Med. 2014 Oct; 174(10): 1668–1673.Retrieved June 15, 2020 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392651/.

Callaway J, Schwab U, Harvma I, et al. (2005). Efficacy of dietary hempseed oil in patients with atopic dermatitis. Journal of Dermatological Treatment 16(2). Retrieved June 15, 2020 from https://www.tandfonline.com/doi/abs/10.1080/09546630510035832.

Campos AC, Moreira FA, Gomes FV, et al. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012 Dec 5; 367(1607): 3364–3378. Retrieved June 15, 2020 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531/.

Campos, A. C., Ortega, Z., Palazuelos, J., et al. (2013). The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: Involvement of the endocannabinoid system. International Journal of Neuropsychopharmacology, 16(6):1407–19. Retrieved June 15, 2020 from https://pubmed.ncbi.nlm.nih.gov/23298518/.

CBD Snapshot. (2019). CBD 101.  Retrieved June 15, 2020 from https://www.cbdsnapshot.com/cbd-101/.

do Nascimento TA, dos Santos Caçula DMR, Temoteo JLM, et al. (2017). Pharmacological and Toxicological Aspects of Cannabis sativa: A systematic review. Journal of Chemical and Pharmaceutical Research 9(3):175–83. Retrieved June 15, 2020 from https://pdfs.semanticscholar.org/ba0b/0b538ae9e021bd903fb8c4ad4af035bfe0fd.pdf.

Dorbian I. (2019). CBD Market Could Pull In $16 Billion By 2025, says study. Retrieved June 15, 2020 from https://www.cannabisbusinesstimes.com/article/cowen-co-analysts-cbd-market-16-billion-2025/.

Iseger TA, Bossong MG. (2015). A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophrenia Research 162(1–3):153–61. Retrieved June 15, 2020 from https://pubmed.ncbi.nlm.nih.gov/25667194/.

Kaur R, Ambwani SR, Singh S. (2016). Endocannabinoid System: A multi-facet therapeutic target. Current Clinical Pharmacology 11(2):10-7. Retrieved June 15, 2020 from https://www.ncbi.nlm.nih.gov/pubmed/27086601.

Klumpers LE, Thacker DL. (2019). A brief background on cannabis: From plant to medical indications. Journal of AOAC International 102(2):412–42. Retrieved June 15, 2020 from https://www.ncbi.nlm.nih.gov/pubmed/30139415.

Laun AS, Shrader SH, Brown KJ, Song ZH. (2018). GPR3, GPR6, and GPR12 as novel molecular targets: Their biological functions and interaction with cannabidiol. Acta Pharmacol Sin. 40(3):300–308. Retrieved June 15, 2020 from https://therichardrosereport.com/gpr3-gpr6-and-gpr12-as-novel-molecular-targets-their-biological-functions-and-interaction-with-cannabidiol/.

LaVito A, Franck T. (2019). New York City plan to fine restaurants using CBD in food and drinks. CNBC. Retrieved June 15, 2020 from https://www.cnbc.com/2019/02/15/new-york-may-start-fining-restaurants-for-using-weed-related-cbd-.html.

Lee M. (2018). CBD and Cannabis Dosage. Project CBD. Retrieved June 15, 2020 from https://www.projectcbd.org/how-to/cbd-dosage-guide.

Maa E, Figi P. (2014, June). The case for medical marijuana in epilepsy. Epilepsia55(6):783–86. Retrieved June 15, 2020 from https://onlinelibrary.wiley.com/doi/full/10.1111/epi.12610.

Meng H, Johnston B, Englesakis M. (2017). Selective Cannabinoids for Chronic Neuropathic Pain: A Systematic Review and Meta-analysis. Anesthesiology Analg 125:1638–52. Retrieved June 15, 2020 from https://pubmed.ncbi.nlm.nih.gov/28537982/.

National Academies of Sciences, Engineering, and Medicine (NASEM). (2017). The health effects of cannabis and cannabinoids: Current state of evidence and recommendations for research. Washington DC: The National Academies Press.

Nielsen S, Sabioni P, Trigo JM, et al. (2017). Opioid-sparing effect of cannabinoids: A systematic review and meta-analysis. Neuropsychopharmacology 42(9):1752–65. Retrieved June 16, 2020 from https://www.ncbi.nlm.nih.gov/pubmed/28327548.

Oláh A, Tóth BI, Borbíró I, et al. (2014). Cannabidiol exerts sebostatis and anti-inflammatory effects on human sebocytes. J Clin Invest. 2014 Sep;124(9):3713-24. Retrieved June 15, 2020 from https://pubmed.ncbi.nlm.nih.gov/25061872/.

Penn Medicine News. (2017). Penn Study Shows Nearly 70 Percent of Cannabidiol Extracts Sold Online Are Mislabeled. Retrieved June 15, 2020 from https://www.pennmedicine.org/news/news-releases/2017/november/penn-study-shows-nearly-70-percent-of-cannabidiol-extracts-sold-online-are-mislabeled.

Porter N. (2017). Three different cannabinoid-based medicines approved by the FDA. Medical Jane. Retrieved June 15, 2020 from https://www.medicaljane.com/2017/05/01/the-3-cannabis-based-medicines-approved-by-the-fda/.

Prescott L. (2018). Marijuana Hemp Stocks. Retrieved June 15, 2020 from http://marijuanahempstocks.com/here-is-why-marijuana-stocks-are-becoming-popular/.

Price M. (2015). Differences between hemp and cannabis. Retrieved June 15, 2020 from https://www.medicaljane.com/2015/01/14/the-differences-between-hemp-and-cannabis/.

Russo EB. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163(7);1344–64. Retrieved June 15, 2020 from https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1476-5381.2011.01238.x.

Scuderi C, Filippis DD, Iuvone T, et al. (2009). Cannabidiol in medicine: A review of its therapeutic potential in CNS disorders. Phytotherapy Research (Review). 23(5): 597–602. Retrieved June 15, 2020 from https://pubmed.ncbi.nlm.nih.gov/18844286/.

United States Department of Agriculture (USDA). (2014). Agricultural Act of 2014: Highlights and Implications. Economic Research Service (Last Updated: 2018, December 21). Retrieved June 15, 2020 from https://www.ers.usda.gov/agricultural-act-of-2014-highlights-and-implications/.

United States Department of Agriculture (USDA). (2019). USDA Update on Farm Bill Implementation Progress Title X Hemp. Retrieved June from https://www.usda.gov/media/press-releases/2019/04/12/usda-update-farm-bill-implementation-progress.

US Food and Drug Administration (USFDA). (2019). FDA warns company marketing unapproved cannabidiol products with unsubstantiated claims to treat cancer, Alzheimer's disease, opioid withdrawal, pain and pet anxiety. Retrieved June 15, 2020 from https://www.fda.gov/news-events/press-announcements/fda-warns-company-marketing-unapproved-cannabidiol-products-unsubstantiated-claims-treat-cancer.

US Food and Drug Administration (USFDA). (2018). FDA News Release. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. Retrieved June 15, 2020 from https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms.

Williamson EM, Evans FJ. (2000). Cannabinoids in clinical practice. Drugs. 2000 Dec;60(6):1303-14. Retrieved June 15, 2020 from https://www.ncbi.nlm.nih.gov/pubmed/11152013.

Xiong W, Cui T, Cheng K, et al. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. Journal of Experimental Medicine 209(6):1121–34. Retrieved June 15, 2020 from http://jem.rupress.org/content/209/6/1121.